ALLMedicine™ Benign Essential Blepharospasm Center
Research & Reviews 46 results
https://doi.org/10.1007/s10792-022-02253-1 10.1097/00002341-199809000-00002 10.1016/j.jns.2015.06.032 10.1016/0039-6257(91)90207-V 10.1111/aos.12002 10.1016/j.ajo.2013.11.014 10.1016/j.jtos.2017.05.008 10.1001/jamaophthalmol.2013.6243 10.1016/j.ophtha.2018.03.013 10.1097/ICO.0000000000000482 10.1167/iovs.06-1507 10.1016/j.preteyeres.2018.04.002 10.1167/iovs.08-2704 10.1097/ICO.0b013e3182261577 10.3390/medicina57030247 10.3346/jkms.2006.21.1.131 10.1167/iovs.17-23500 10.1007/s10384-016-0469-6 10.1590/S0004-27492011000600006 10.1016/j.ophtha.2012.03.004 10.1016/S0161-6420(87)33337-8 10.1007/PL00007813 10.1001/archneur.59.3.418 10.5301/ejo.5000482 10.1136/bjo.87.1.54 10.1038/eye.2015.18 10.1038/s41598-018-26750-5 10.1016/j.jtos.2017.03.006 10.1167/iovs.05-1654 10.3928/1542-8877-20060301-06 10.4274/tjo.43.48303 10.1016/S0161-6420(97)30125-0 10.1097/SCS.0000000000002435 10.1097/01.iop.0000231774.70194.3f 10.1097/ICO.0000000000000688 10.1167/iovs.10-7093 10.1136/bjo.76.3.157 10.1016/S0002-9394(02)01430-7 10.1167/iovs.03-0839 10.1016/j.ophtha.2003.06.027 10.3928/1081-597X-20040501-08 10.2147/OPTH.S305817 10.1111/ceo.12165 10.4103/ijo.IJO_41_19
International Ophthalmology; Bayraktar Bilen N, Bilen Ş et. al.
Apr 1st, 2022 - To investigate the effect of botulinum neurotoxin-A (BTX-A) treatment on dry eye symptoms, tear meniscus, corneal topography and corneal aberrometry in patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS). This prospective...
https://doi.org/10.3233/NRE-228015
NeuroRehabilitation Bansal S, Green K
Mar 29th, 2022 - Tinted lenses have been used to manage visual discomfort and photosensitivity in patients with migraines, benign essential blepharospasm (BEB) and epilepsy. The purpose of this review is to examine the existing clinical research regarding the use ...
https://doi.org/10.1007/s40477-021-00613-8 10.1093/brain/108.3.593 10.4274/tjo.27879 10.1016/j.nicl.2018.06.004 10.1007/s00415-014-7359-y 10.1111/j.1468-1331.2007.02034.x 10.1097/WNO.0b013e31828f69e5 10.1016/j.neulet.2017.09.014 10.1212/01.WNL.0000063306.67984.8C 10.1097/00041327-200303000-00003 10.1007/s00417-006-0392-5 10.1038/eye.1993.147 10.7863/jum.1993.12.8.473 10.1038/eye.1993.16 10.1186/1471-2474-13-209
Journal of Ultrasound; Kesimal B, Kesimal U et. al.
Dec 3rd, 2021 - Benign essential blepharospasm (EB) is a focal facial dyskinesia that occurs with the involuntary contraction of muscles around the eyes. In the literature, studies on blepharospasm focus on elucidating the pathophysiology of this condition in the...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238266
Medicine Badarny S, Ibrahim R et. al.
Jun 24th, 2021 - Botulinum toxin A is considered an effective treatment for involuntary facial movements. We examined whether treatment efficacy maintained or changed over time with two products, Botox and Dysport, in patients with hemifacial spasm, facial synkine...
https://doi.org/10.1016/j.ajo.2021.04.029
American Journal of Ophthalmology; Sanguandikul L, Apinyawasisuk S et. al.
May 10th, 2021 - The purpose of this study was to compare ocular complications and efficacy of preseptal (PST) versus those of pretarsal (PTS) botulinum toxin type A (BoNT-A) therapy in cases of benign essential blepharospasm (BEB). Randomized clinical trial. Sett...
Drugs 2 results see all →
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT00234507
Jul 29th, 2019 - The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
https://clinicaltrials.gov/ct2/show/NCT02370875
Dec 13th, 2017 - A two week course of rTMS therapy to achieve sustained benefits will be employed. With standard BoNT treatment, the peak-dose benefits are seen at about 4-6 weeks after the administration of injections. rTMS will be introduced during this peak-dos...
News 6 results
https://www.medscape.com/viewarticle/962762
Nov 11th, 2021 - Cannabis oil may reduce the duration and frequency of spasms caused by benign essential blepharospasm (eye twitching), researchers say. The treatment could serve as a second-line treatment for patients who have already received botulinum toxin inj...
https://www.medscape.com/viewarticle/912928
May 13th, 2019 - PHILADELPHIA — The US Food and Drug Administration (FDA) has approved broadening the indication for incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) as first-line therapy for blepharospasm in adult patients, the manufacturer has announced. Benig...
https://www.medscape.com/viewarticle/912886
May 10th, 2019 - PHILADELPHIA — IncobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) conveys long-term safety and efficacy in patients with benign essential blepharospasm (BEB) who are botulinum toxin-naïve, new research suggests. BEB is a focal dystonia that causes...
https://www.staging.medscape.com/viewarticle/752573
Oct 31st, 2011 - October 31, 2011 (Orlando, Florida) — A new study shows that shorter injection intervals with incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals), given on an as-needed basis, are safe and effective. The study provides much-needed proof that it is ...
https://www.medscape.com/viewarticle/752573
Oct 31st, 2011 - October 31, 2011 (Orlando, Florida) — A new study shows that shorter injection intervals with incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals), given on an as-needed basis, are safe and effective. The study provides much-needed proof that it is ...
